Roche’s CT-388 weight-loss shot hits 22.5% in Phase 2, sets up pivotal trials
Berlin, Jan 27, 2026, 20:02 CET On Tuesday, Roche revealed that its experimental obesity drug CT-388 led patients to shed up to 22.5% of their body weight in a mid-stage trial. The Swiss pharma giant plans to leverage these results to advance